Greenwich LifeSciences, Inc. GLSI
15.17 USD +0.52 (+3.55%)
At closeNov 6, 2026, 4:00 PM EST
15.50 +0.33 +2.18%
After hours · Nov 6, 4:00 PM ET
14.54 Day range 15.75
7.85 52-week range 33.56
- YTD
- -27.80%
- 1 year
- +84.55%
- Market cap
- 222.67M
- EPS (ttm)
- -1.53
- Shares out
- 13.14M
- Forward P/E
- -14.83
- YTD return
- -27.80%
- 1-year return
- +84.55%
- Volume
- 80.86K
- Avg volume
- 129.97K
- Open
- 14.91
- Previous close
- 14.65
- Day's range
- 14.54 – 15.75
- 52-week range
- 7.85 – 33.56
- Beta
- 3.32
- Price target
- 38.00 (+150.5%)
- Earnings date
- Aug 14, 2024
ALL +10.17 (+203.40%)
Key statistics
- Enterprise value
- 171.41M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 23.30
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -3.15M
- Total cash
- 7.22M
- Total debt
- 0
- Return on equity
- -123.67%
- Short % of float
- 7.83%
- 50-day average
- 13.57
- 200-day average
- 14.65
Analyst view
Price target (mean) 38.00
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate 0.00.
Financials — quick view
GLSI Revenue — quarterly 0
GLSI Net income — quarterly -3.95M
GLSI EPS — quarterly -0.27
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.21 | -0.20 | +0.01 | +4.76% |
| Aug 14, 2024 | Jun 1, 2024 | -0.20 | -0.20 | 0.00 | 0.00% |
| Aug 14, 2024 | Jun 1, 2024 | -0.20 | — | — | — |
| May 20, 2024 | Mar 1, 2024 | -0.20 | -0.19 | +0.01 | +5.00% |
| May 20, 2024 | Mar 1, 2024 | -0.20 | — | — | — |
| Apr 15, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 23, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| May 22, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Feb 28, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Feb 20, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Apr 10, 2023 | HC Wainwright & Co. | reit | — | Buy |
| Sep 1, 2021 | HC Wainwright & Co. | init | — | Buy |
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- greenwichlifesciences.com
News
Greenwich LifeSciences Extends 100% Insider Share Lock‑Up To January 31, 2027 
HC Wainwright & Co. Maintains Buy on Greenwich LifeSciences, Raises Price Target to $69 
Greenwich LifeSciences Expects Q2 Cash Burn To Be ~$2M, Down From $4.7M In Q1, With Cash Balance Of ~$8.9M As Of June And Expected Burn Rate Of $2-4M Per Quarter Going Forward - Greenwich LifeSciences Receives Approval From European Medicines Agency To Combine HLA-A*02, Non-HLA-A*02 Participants In Europe
Greenwich LifeSciences Receives EMA Approval To Use Commercially Manufactured GP2 In Its FLAMINGO-01 Phase III Clinical Trial - Greenwich LifeSciences Q4 EPS $(0.58) Misses $(0.31) Estimate
Greenwich LifeSciences Announces Published Abstract And Poster On Its Phase III FLAMINGO-01 Trial For GLSI-100 To Prevent Breast Cancer Recurrences From The ASCO Annual Meeting 2026 
Greenwich LifeSciences Reports Progress in Late-Stage Breast Cancer Immunotherapy Trial 
Greenwich LifeSciences Receives Nasdaq Noncompliance Notice 
Why Kyverna Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
Your note
Sign in to keep a note on GLSI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| PATEL SNEHAL | Chief Executive Officer | Purchase | Sep 25, 2024 | 5,536,100 |
| THOMPSON JAYE L | Officer | Purchase | Nov 20, 2024 | 264,148 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 2.66% | 350,144 | 4.26M | Sep 29, 2024 |
| Vanguard Group Inc | 2.08% | 273,525 | 3.33M | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.02% | 133,550 | 1.62M | Sep 29, 2024 |
| Credit Agricole S.A. | 0.66% | 87,000 | 1.06M | Sep 29, 2024 |
| Northern Trust Corporation | 0.57% | 74,500 | 905.92K | Sep 29, 2024 |
| State Street Corporation | 0.54% | 71,408 | 868.32K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.17% | 153,459 | 1.87M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.08% | 141,696 | 1.72M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.54% | 71,311 | 867.14K | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.47% | 61,696 | 750.22K | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.39% | 50,661 | 616.04K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.25% | 32,217 | 391.76K | Oct 30, 2024 |